HIVE Blockchain Technologies (CVE:HIV – Get Free Report) was upgraded by analysts at Roth Capital to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.
Several other research firms also recently commented on HIV. Northland Capmk raised shares of HIVE Blockchain Technologies to a “strong-buy” rating in a report on Thursday, September 19th. Cantor Fitzgerald raised HIVE Blockchain Technologies to a “strong-buy” rating in a report on Tuesday, October 29th.
Get Our Latest Stock Analysis on HIV
HIVE Blockchain Technologies Price Performance
Read More
- Five stocks we like better than HIVE Blockchain Technologies
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Why Wall Street Sees Major Upside for PayPal Stock
- What is the Dogs of the Dow Strategy? Overview and Examples
- Cintas Shares Slide: A Prime Opportunity to Buy the Dip
- Basic Materials Stocks Investing
- Tempus AI: A Potential Double-Bagger After Recent Pullback
Receive News & Ratings for HIVE Blockchain Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HIVE Blockchain Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
